Immersion Corporation (NASDAQ:IMMR) is a provider of haptic technologies that allow people to use their sense of touch when operating a variety of digital devices. The Company develops and market or license a ranges of software technologies and products. The Company is focusing its marketing and business development activities on markets, such as mobile communications and consumer electronics, automotive, gaming, commercial and industrial, and medical. Immersion Corporation (NASDAQ:IMMR) shares after opening at $10.54 on last trade day and at the end of the day closed at $11.30. Company price to sales ratio in past twelve months was calculated as 6.70 and price to cash ratio as 4.47. Immersion Corporation (NASDAQ:IMMR) showed a positive weekly performance of 7.01%.
ProShares Ultra S&P500 (ETF) (NYSEARCA:SSO), a premier provider of alternative exchange traded funds, today announced the launch of the ProShares DJ Brookfield Global Infrastructure ETF (TOLZ), the first ETF providing “pure-play” exposure to infrastructure. “Infrastructure investment has become attractive because of growing global demand, increasing opportunities for private sector investment, and high barriers to entry that limit competition,” said Michael Sapir, Chairman and CEO of ProShare Advisors LLC, ProShares’ investment advisor. “We are pleased to offer the first ETF that invests exclusively in companies whose primary business is the ownership and operation of infrastructure.” ProShares Ultra S&P500 (ETF) (NYSEARCA:SSO) shares advanced 1.26% in last trading session and ended the day on $106.66. ProShares Ultra S&P500 (ETF) (NYSEARCA:SSO) yearly performance is 45.99%.
Citigroup views shares of Gilead Sciences, Inc. (NASDAQ:GILD) as “cheap” at current levels and keeps a Buy rating on the name with a $96 price target. Citi expects Gilead to generate $117B in free cash flow over the next 10 years and have $100B by 2023. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved up 3.92% in last trading session and was closed at $73.64, while trading in range of $72.14 – $73.88. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is -1.94%.
On March 17, Synergy Pharmaceuticals Inc (NASDAQ:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C). Synergy Pharmaceuticals Inc (NASDAQ:SGYP) weekly performance is -7.85%. On last trading day company shares ended up $5.28. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) distance from 50-day simple moving average (SMA50) is -6.15%. Analysts mean target price for the company is $13.21.